Literature DB >> 28888949

Deficiency of N-acetyltransferase increases the interactions of isoniazid with endobiotics in mouse liver.

Pengcheng Wang1, Amina I Shehu1, Jie Lu1, Rujuta H Joshi1, Raman Venkataramanan1, Kim S Sugamori2, Denis M Grant2, Xiao-Bo Zhong3, Xiaochao Ma4.   

Abstract

Acetylation is the major metabolic pathway of isoniazid (INH) mediated by N-acetyltransferases (NATs). Previous reports suggest that slow acetylators have higher risks of INH hepatotoxicity than rapid acetylators, but the detailed mechanisms remain elusive. The current study used Nat1/2(-/-) mice to mimic NAT slow metabolizers and to investigate INH metabolism in the liver. We found that INH acetylation is abolished in the liver of Nat1/2(-/-) mice, suggesting that INH acetylation is fully dependent on NAT1/2. In addition to the acetylation pathway, INH can be hydrolyzed to form hydrazine (Hz) and isonicotinic acid (INA). We found that INA level was not altered in the liver of Nat1/2(-/-) mice, indicating that deficiency of NAT1/2 has no effect on INH hydrolysis. Because INH acetylation was abolished and INH hydrolysis was not altered in Nat1/2(-/-) mice, we expected an extremely high level of INH in the liver. However, we only observed a modest accumulation of INH in the liver of Nat1/2(-/-) mice, suggesting that there are alternative pathways in INH metabolism in NAT1/2 deficient condition. Our further studies revealed that the conjugated metabolites of INH with endobiotics, including fatty acids and vitamin B6, were significantly increased in the liver of Nat1/2(-/-) mice. In summary, this study illustrated that deficiency of NAT1/2 decreases INH acetylation, but increases the interactions of INH with endobiotics in the liver. These findings can be used to guide future studies on the mechanisms of INH hepatotoxicity in NAT slow metabolizers.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug metabolism; Isoniazid; N-acetyltransferase; Slow metabolizers

Mesh:

Substances:

Year:  2017        PMID: 28888949      PMCID: PMC5681379          DOI: 10.1016/j.bcp.2017.09.001

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  43 in total

Review 1.  The manifold of vitamin B6 dependent enzymes.

Authors:  G Schneider; H Käck; Y Lindqvist
Journal:  Structure       Date:  2000-01-15       Impact factor: 5.006

2.  Pyridoxine and the isoniazid-induced neuropathy.

Authors:  W MANDEL
Journal:  Dis Chest       Date:  1959-09

3.  Pharmacokinetics of isoniazid metabolism in man.

Authors:  G A Ellard; P T Gammon
Journal:  J Pharmacokinet Biopharm       Date:  1976-04

4.  A systems biology approach utilizing a mouse diversity panel identifies genetic differences influencing isoniazid-induced microvesicular steatosis.

Authors:  Rachel J Church; Hong Wu; Merrie Mosedale; Susan J Sumner; Wimal Pathmasiri; Catherine L Kurtz; Mathew T Pletcher; John S Eaddy; Karamjeet Pandher; Monica Singer; Ameesha Batheja; Paul B Watkins; Karissa Adkins; Alison H Harrill
Journal:  Toxicol Sci       Date:  2014-05-20       Impact factor: 4.849

5.  Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat.

Authors:  S D Nelson; J R Mitchell; J A Timbrell; W R Snodgrass; G B Corcoran
Journal:  Science       Date:  1976-09-03       Impact factor: 47.728

6.  Metabolomic analysis reveals novel isoniazid metabolites and hydrazones in human urine.

Authors:  Feng Li; Yan Miao; Lirong Zhang; Sarah Ann Neuenswander; Justin T Douglas; Xiaochao Ma
Journal:  Drug Metab Pharmacokinet       Date:  2011-08-16       Impact factor: 3.614

7.  Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure.

Authors:  Imir G Metushi; Corron Sanders; William M Lee; Jack Uetrecht
Journal:  Hepatology       Date:  2014-01-27       Impact factor: 17.425

8.  The effect of ageing on isoniazid pharmacokinetics and hepatotoxicity in Fischer 344 rats.

Authors:  John Mach; Aniko Huizer-Pajkos; Sarah J Mitchell; Catriona McKenzie; Leo Phillips; Alice Kane; Brett Jones; Rafael de Cabo; Victoria Cogger; David G Le Couteur; Sarah N Hilmer
Journal:  Fundam Clin Pharmacol       Date:  2015-11-09       Impact factor: 2.748

Review 9.  Isoniazid metabolism and hepatotoxicity.

Authors:  Pengcheng Wang; Komal Pradhan; Xiao-Bo Zhong; Xiaochao Ma
Journal:  Acta Pharm Sin B       Date:  2016-08-03       Impact factor: 11.413

10.  Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy.

Authors:  Feng Li; Jie Lu; Jie Cheng; Laiyou Wang; Tsutomu Matsubara; Iván L Csanaky; Curtis D Klaassen; Frank J Gonzalez; Xiaochao Ma
Journal:  Nat Med       Date:  2013-03-10       Impact factor: 53.440

View more
  2 in total

1.  Cell Type-Specific Roles of CD38 in the Interactions of Isoniazid with NAD+ in the Liver.

Authors:  Junjie Zhu; Jie Lu; Hung-Chun Tung; Ke Liu; Jianhua Li; Denis M Grant; Wen Xie; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2020-10-05       Impact factor: 3.922

2.  Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury.

Authors:  Yifan Bao; Xiaochao Ma; Theodore P Rasmussen; Xiao-Bo Zhong
Journal:  Curr Pharmacol Rep       Date:  2018-03-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.